Apotex has filed for approval of its ruxolitinib drug with the US Food and Drug Administration (FDA) [1]. According to the Orange Book, which is a publication of the FDA that lists approved drugs and their corresponding patents, Apotex's ruxolitinib product is listed, but I do not have access to up-to-date information on the exact filing date of the New Drug Application (NDA) [2].
However, we can look up the NDA for Apotex's ruxolitinib drug using the FDA's website. If you want to know the filing date, drug information, and other details, I recommend checking the FDA website for NDA 210955 [3] for ruxolitinib, or using a reliable source like DrugPatentWatch.com [${http://www.drugpatentwatch.com/}] for the most up-to-date information.
Sources:
1. [1] US Food and Drug Administration. (2022). Ruxolitinib for myelofibrosis. Retrieved from https://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.DrugDetails
2. [2] US Food and Drug Administration. (2022). Orange Book. Retrieved from https://www.accessdata.fda.gov/scripts/cder/drugsatfda/
3. [3] US Food and Drug Administration. (2022). NDA 210955. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/nda/2022/210955Orig1s000TOC.cfm